Crohn's disease

Children diagnosed with IBD can develop other immune-related diseases, growth and weight problems, skin conditions, and serious infections over time. Knowing the frequency and risk factors helps families and clinicians...

Physical activity is linked to general health and quality of life. If people with IBD—particularly those with more severe CD—are less active, tailored support could help improve wellbeing and manage disease-related...

Diarrhea is a common, burdensome symptom in IBD. This study suggests that inflammation-linked defects in enterocyte differentiation and reduced ion transporter expression may help explain persistent diarrhea and that...

Patients and clinicians considering long-term use of mirikizumab for Crohn's disease may find evidence here that quality of life and common symptoms (fatigue, abdominal pain, stool frequency) can remain improved out to...

Late-stage (Phase 3) AFFIRM data for subcutaneous Skyrizi in Crohn’s disease are being presented publicly — that could lead to new treatment options if regulators approve expanded indications, and it influences...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Symptoms and flares. The original article is from msn.com.

Cure8 could only read part of this source from tampabay28.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Community and awareness.

Many people with Crohn’s experience inflammation outside the gut that can affect joints, eyes, skin, gallbladder, kidneys, and bones. Recognizing these signs can help patients and clinicians connect seemingly unrelated...

This study links altered autophagy genes (ATG5, ATG16L1) in Crohn’s disease and ulcerative colitis with modulation by the gut bacterium Akkermansia muciniphila and its extracellular vesicles, suggesting a possible...

The study found higher recorded rates of hidradenitis suppurativa in people with Crohn’s disease and psoriatic arthritis, and a smaller increase in ulcerative colitis, suggesting clinicians should consider asking about...

Positive phase 3 results for a subcutaneous risankizumab induction regimen may expand access to an IL‑23 p19 therapy option that avoids IV induction and showed strong short-term remission and endoscopic response rates in...

Positive Phase 3 data for Skyrizi in Crohn’s could affect treatment options and access if regulators expand the drug’s label and insurers update coverage; for patients and clinicians it may signal an additional biologic...

The timing of depression versus GI diagnoses differs by condition: depression commonly comes before IBS but often follows Crohn’s disease. That matters because it suggests different gut–brain pathways and could change...

Fusing blood tests, CT enterography radiomics, and deep-learning analysis of deep small-bowel endoscopy images may improve detection of active small-bowel Crohn’s disease — a common clinical challenge because many...

This analysis suggests a subcutaneous formulation of infliximab may lead to better clinical and endoscopic outcomes than intravenous infliximab for ileal-involved Crohn’s disease, which could affect treatment choices and...

Positive Phase 3 data for a subcutaneous formulation of risankizumab (SKYRIZI) in Crohn’s disease could expand treatment options for people with moderate-to-severe Crohn’s and influence prescribing and insurance coverage...

Phase III AFFIRM results suggest a subcutaneous risankizumab regimen may increase endoscopic remission in Crohn’s disease, which matters for patients and clinicians weighing biologic options and for regulatory approval...

A Phase 3 positive result for subcutaneous SKYRIZI could expand treatment options for people with Crohn’s disease by offering a more convenient dosing route and may affect how available drugs like Rinvoq are used. It...

Cure8 found this source from app.dealroom.co, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

This study follows people from diagnosis and shows that about half achieve clinically meaningful improvements in quality of life by 3 years, but many remain below general population norms.

Patients on biologic therapy often have drug levels and antidrug antibodies measured to guide care. This study suggests prior biologic history, disease type (UC vs CD) and which biologic is currently used may affect...

This study points to possible differences in fiber intake and the food sources of tryptophan between IBD patients and healthy people—factors that could be relevant for future dietary guidance or research, but the results...

Automated Lewis score estimation could make capsule endoscopy readings faster and more consistent, which may help track small-bowel Crohn disease activity. This study shows preliminary feasibility but not readiness for...

TG2 produced by intestinal myofibroblasts may drive fibrosis and strictures in Crohn's disease independently of inflammation; blocking TG2 reduced fibrosis in lab and mouse models, pointing to a possible new...

This large, long-term study suggests that having pets or farm animals during pregnancy or early childhood probably does not meaningfully change a child’s later risk of developing IBD, which may reassure families...

New Phase 3 data suggest subcutaneous risankizumab (Skyrizi) can achieve meaningful endoscopic remission and ulcer-free endoscopy rates in adults with active Crohn's disease, including higher responses in patients...

Endoscopic remission (visual healing) is linked to better long-term outcomes in Crohn's disease. An approved subcutaneous induction option could make risankizumab easier to use outside infusion settings.

MASLD was common in this IBD cohort and became more frequent as BMI increased; clinicians and patients may need to consider liver health when managing IBD, especially for people with overweight or obesity.

RDW-CV, a routine blood-test parameter, may help signal higher inflammatory activity in ulcerative colitis and provide low-cost adjunctive information when assessing disease activity.

This trial focuses on fibrostenosing Crohn’s disease, a form of IBD where strictures can block the intestine; a successful drug could offer a medical option to improve endoscopic passability and reduce need for...

Cure8 could only read part of this source from tradingview.com, so this card uses cautious topic tags instead of a full summary. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab.

This advances a drug candidate (ontunisertib) aimed specifically at fibrostenosing Crohn’s disease — a form of IBD where strictures can block the bowel and endoscopic passability is a meaningful clinical measure.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Celiac Disease, and Medications. The original article is from British medical journal.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Community and awareness. The original article is from British medical journal.

Cure8 found this source from amjcaserep.com, but the page could not be read reliably yet. It is tagged for Crohn's disease and Pediatrics and family. Open the original article for the full details.

A new subcutaneous option for risankizumab (SKYRIZI) showed higher rates of endoscopic remission and ulcer-free endoscopy versus placebo in a Phase 3 Crohn's disease trial, which could expand at-home biologic options if...

Cure8 found this source from streetinsider.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Risankizumab, and IL-23 inhibitor. Open the original article for the full details.

New Phase 3 AFFIRM data for subcutaneous Skyrizi (risankizumab) in Crohn’s disease was released and coincided with a notable AbbVie stock drop, suggesting investor concern about the results.

Cure8 found this source from marketwatch.com, but the page could not be read reliably yet. It is tagged for Crohn's disease, Inflammatory bowel disease, and Risankizumab. Open the original article for the full details.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease and Complications. The original article is from British medical journal.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from British medical journal.

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Diet and lifestyle. The original article is from British medical journal...

Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from British medical journal...

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal (Clinical...

First-person perspectives can help patients and caregivers see practical coping strategies, emotional framing, and system-level supports others have used. This piece may offer encouragement and real-world ideas for...

IBD affects more than the digestive tract and long-term care now emphasizes controlling inflammation and monitoring (including endoscopic healing) to lower complication risk and improve quality of life.

Based on the title and source metadata, this appears to be a case report related to Crohn's disease, Inflammatory bowel disease, and Tests and monitoring. The original article is from British medical journal (Clinical...

Based on the title and source metadata, this appears to be a patient education related to Crohn's disease, Inflammatory bowel disease, and Research and clinical trials. The original article is from Gut.